Core Viewpoint - BioMarin Pharmaceutical Inc. has successfully acquired Amicus Therapeutics for nearly $5 billion, which is expected to enhance its commercial portfolio and revenue growth significantly. Group 1: Acquisition Details - BioMarin entered into a definitive agreement to acquire Amicus Therapeutics for $14.50 per share, representing a 33% premium over Amicus's closing price on December 18 [2] - The acquisition will be funded through cash on hand and approximately $3.7 billion of non-convertible debt financing [3] Group 2: Financial Impact - The acquisition is anticipated to support BioMarin's long-term compound annual growth rate (CAGR) through 2030, with the two new treatments generating combined net product revenues of $599 million in the past year [4] - The transaction is expected to accelerate revenue growth and strengthen BioMarin's financial outlook, being accretive to Non-GAAP Diluted EPS within the first 12 months post-closure [5] Group 3: Market Performance - Following the announcement of the acquisition, BioMarin's stock surged 17.71% to close at $61.15, marking its third consecutive day of gains [1]

Company Overview - Ondas Holdings Inc. (NASDAQ:ONDS) experienced a significant stock increase of 18.21% on Friday, closing at $9.22 per share, driven by the creation of a new executive role and the appointment of a retired US Army general [1][2]. Executive Appointment - The company has established a Chief Operating Officer (COO) position, which will be filled by Brigadier General Patrick Huston, who will also retain his role as general counsel [2][3]. - Huston joined the Ondas Autonomous Systems advisory board in September 2025 and will now lead operational execution, focusing on disciplined programs, integration of acquisitions, and scaling operations across subsidiaries [3]. Responsibilities and Strategic Importance - In his new role, Huston will oversee legal, regulatory, compliance, and corporate governance functions, which are crucial for Ondas Holdings' engagement with US and allied government customers [4]. - The appointment reflects the growing need for integrated legal and operational leadership as the company expands in defense, security, and government markets [5].

Core Points - CoreWeave Inc. (NASDAQ:CRWV) experienced a significant increase of 22.64% on Friday, closing at $83, driven by renewed coverage from Citigroup and overall investor optimism [1][2] - Citigroup issued a "buy" recommendation for CoreWeave, although it reduced its price target by 30% from $192 to $135, indicating a 62% upside potential from the latest closing price [2][3] - The company reported strong bookings growth of 85% quarter-over-quarter and 270% year-over-year in Q3, but faced supply constraints that delayed revenue and capital expenditures from Q4 to Q1 2026 [2][3] - Management insights suggest that CoreWeave's capacity and bookings are expected to continue expanding in Q4, which may support growth acceleration in 2026 [3] - Financially, CoreWeave is positioned well with over 60% of its revenue linked to investment-grade customers and plans to announce a new credit facility in the first half of next year, which is anticipated to lower its cost of capital [3]

Group 1 - Firefly Aerospace Inc. (NASDAQ:FLY) experienced a significant stock price increase of 22.82%, closing at $24.65, following optimistic initial coverage from an analyst [1][2] - Keybanc issued a "sector weight" rating on Firefly Aerospace, expressing optimism about the company's spacecraft operations, although profitability may take time to achieve [1][2] - The company is working on establishing a consistent launch track record and is making progress with its medium-lift rocket [2] Group 2 - Firefly Aerospace announced that certain shareholders plan to sell over 11 million shares at a price of $50 each, totaling $555.6 million, with proceeds going entirely to the selling shareholders [2][3] - The sale follows Firefly's successful acquisition of SciTec Innovations, LLC, a company specializing in advanced national security technologies and missile warning systems [3]

Core Insights - Amicus Therapeutics, Inc. has experienced a significant stock price increase of 30.21%, closing at $14.18, following the announcement of its merger with BioMarin Pharmaceutical for nearly $5 billion [1][2] - The acquisition deal is an all-cash transaction priced at $14.50 per share, representing a 33% premium over Amicus's previous closing price of $10.89 [3] - The merger has received approval from both companies' boards but is still pending regulatory and shareholder approvals [3] Company Performance - Amicus Therapeutics reached a new 52-week high during trading, peaking at $14.36 before closing at $14.18 [2] - The company has developed two transformative medicines for rare diseases, impacting over 3,400 patients globally [4] Strategic Outlook - The CEO of Amicus Therapeutics expressed confidence that the merger will enhance the reach of its medicines, benefiting more patients and accelerating progress in the rare disease community [5]

We recently published 10 Firms in the Limelight. Intuitive Machines Inc. (NASDAQ:LUNR) is one of the best performers on Friday. Intuitive Machines rallied for a second day on Friday, soaring 37.70 percent to close at $14.94 apiece as investors took heart from a bullish rating and price target from an investment firm. In its initial coverage of the stock, Keybanc issued a “buy” recommendation and $20 price target on Intuitive Machines Inc. (NASDAQ:LUNR). The figure marked a 34 percent upside potential fro ...

Plug Power stock has performed poorly over the past few years, but that could change soon.If you're looking for a stock that will provide stability and remove volatility from your portfolio, turn around now. Plug Power (PLUG 2.88%) is not for you. Plug Power, an industry leader in hydrogen fuel cell technology, is truly only suitable for investors with a longer time horizon and those who have the stomach for high-risk, high-reward stocks.NASDAQ : PLUGPlug PowerToday's Change( -2.88 %) $ -0.07Current Price$ ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Inspire Medical To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Inspire Medical between August 6, 2024 and August 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Dec. 20, 2025 (GLOBE NEWSWI ...

Petrobras ( PBR ) is the largest integrated oil & gas company in South America. They dominate the Brazilian upstream and midstream oil & gas market. With 11.4 billion barrels of oil equivalent "BOE" reserves as of 2024, they are atBashar is a contributing writer at Seeking Alpha, focusing on Long/Short investment ideas, with a geographic focus in North America. Before that, Bashar worked at an Investment Fund in the United Kingdom. He has a Master's degree in Finance from the Queen Mary University of London ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...